Pharvaris NV
pharvaris.comWhat Do They Do?
Develops oral therapies to prevent and treat attacks of hereditary and acquired angioedema for people with these rare diseases.
20-F for FY2025, filed Apr 2, 2026We are a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases…View ↗
Deucrictibant may address unmet medical needs of people living with AE-BK by both preventing attacks from occurring, using an…View ↗
In October 2025, we initiated CREAATE, a global, pivotal Phase 3 study to assess the efficacy and safety of deucrictibant for the…View ↗
Who Do They Compete With?
Competes with Astria, Intellia, and ADARx
20-F for FY2025, filed Apr 2, 2026We are also aware of a number of HAE therapies in clinical development: STAR-0215 from Astria, a long-lived monoclonal antibody inhibitor…View ↗
Loading...
